CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 7,287 enrolled
Drug / intervention
hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agentsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00324350
NCT00324350Phase 3Completed
CompareCT.gov

Intensive Glycemic Control and Skeletal Health Study - Ancillary Study to the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD-BONE)

University of California, San Francisco·interventional·Posted May 11, 2006·Updated Oct 5, 2012

In Brief

A Phase 3 clinical trial evaluating hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents for Atherosclerosis and 5 related conditions. Completed, enrolled 7,287 participants across 5 sites in 2 countries.

Detailed Summary

The purpose of the ACCORD-BONE Study is to investigate the effects of intensive glycemic control for type 2 diabetes (in ACCORD participants) on factors related to bone health, including, fractures, falls, and bone mineral density.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Coronary Disease
CountriesCanada, United States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 11, 2006
Enrollment StartOct 1, 2003
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 20.1 years ago

Interventions

hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agentsdrug

type 2 diabetes treatments, per standard of care